Researchers will identify miRNA biomarkers for congenital HD.
Rosetta Genomics extended an existing collaboration with NYU School of Medicine to include research into congenital heart disease (CHD). Investigators will be screening for specific miRNA biomarkers and signatures that may be used to diagnose and target CHD in newborns.
“It is now clear that miRNAs play a key role in controlling diverse aspects of cardiac development and response to disease,” notes David B. Meyer, M.D., director of pediatric and congenital cardiothoracic surgery at NYU School of Medicine. “Rosetta Genomics’ extensive knowledge and proprietary technologies in the miRNA field, coupled with our experience in CHD, is an excellent starting point for this collaboration.”
